Van Der Poel et al., 2010 - Google Patents
Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgGVan Der Poel et al., 2010
View HTML- Document ID
- 13875613991265403554
- Author
- Van Der Poel C
- Karssemeijer R
- Boross P
- Van Der Linden J
- Blokland M
- Van De Winkel J
- Leusen J
- Publication year
- Publication venue
- Blood, The Journal of the American Society of Hematology
External Links
Snippet
FcγRI is the sole high-affinity immunoglobulin G (IgG) receptor on leukocytes. Its role in immunity and the clearance of opsonized particles has been challenged, as the receptor function may well be hindered by serum IgG. Here, we document immune complex binding …
- 230000027455 binding 0 title abstract description 168
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Der Poel et al. | Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG | |
| Zhang et al. | The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions | |
| Bulliard et al. | Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies | |
| Du et al. | A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy | |
| Buatois et al. | Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia | |
| Jacobi et al. | Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls | |
| Oostindie et al. | DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies | |
| US20200385471A1 (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases | |
| Awan et al. | CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody | |
| RU2769949C2 (en) | Biological materials and their application methods | |
| JP5560301B2 (en) | Therapeutic and diagnostic methods and compositions targeting 4IG-B7-H3 and its corresponding NK cell receptor | |
| Holgado et al. | CD32 ligation promotes the activation of CD4+ T cells | |
| Schwartz et al. | Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor | |
| Swisher et al. | The many faces of FcγRI: implications for therapeutic antibody function | |
| JP2020143108A (en) | Combination therapies with anti-cd38 antibodies | |
| Manetta et al. | Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor | |
| JP2019529373A (en) | Anti-Tim-3 antibody and use thereof | |
| Kassem et al. | SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma | |
| Pouleau et al. | Preclinical characterization of ISB 1342, a CD38× CD3 T-cell engager for relapsed/refractory multiple myeloma | |
| Zhang et al. | A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity | |
| Ferrari et al. | Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies | |
| Schanin et al. | Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells | |
| Evers et al. | Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies | |
| Caracciolo et al. | Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia | |
| Grandclément et al. | Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma |